Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

2020

2020

  • 2020 - 07 - 23

    Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant

    WALTHAM, Mass. – Florence, Italy, July 23, 2020 – The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced today that the companies have entered into an exclusive global license agreement for development and commercialization of elacestrant.
  • 2020 - 07 - 22

    Dermatix(R) Unveils New Product Breakthrough for Acne Scarring Solution

    23 July 2019, Kula Lumpur - Dermatix®, a brand of A.Menarini Singapore Pte.Ltd has just launched its new acne scar care, Dermatix® Acne Scar. Formulating with Niacinamide (Vitamin B3), Alpha Hydroxy Acids (AHAs) and antioxidants, it delivers a gentle exfoliation to repair acne scars for an overall more even skin tone. Created by top derma experts in Europe, it is now available in Malaysia -the Asia Pacific's first country in launching the product.
  • 2020 - 06 - 09

    Menarini Group Completes Acquisition of Stemline Therapeutics

    FLORENCE – June 10, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash consideration up to $677 million on a fully diluted basis.
  • 2020 - 06 - 03

    Menarini invests 150 million euros in a new pharmaceutical plant in Italy

    Menarini invests 150 million euros in a new pharmaceutical plant in Italy: its name will be linked to the relaunch of the country Lucia and Alberto Giovanni Aleotti: "A heartfelt choice for our country"
  • 2020 - 06 - 03

    Tillotts and Menarini Receive Regulatory Approval for Asacol® 400 and 800 mg Tablets in the People's Republic of China

    RHEINFELDEN, Switzerland, June 4th, 2020 – Tillotts Pharma AG ("Tillotts"), part of the Japanese Zeria Group, and A. Menarini International Trading (Wuhan) Co. Ltd. ("Menarini"), a member of the Italian A. Menarini Group, are pleased to announce the regulatory approval for Asacol® 400 and 800 mg tablets in the People’s Republic of China (“China”).
  • 2020 - 05 - 03

    Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

    FLORENCE and NEW YORK – May 4, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which Menarini Group will acquire Stemline in a transaction valued up to $677 million.